argenx
Autoimmune diseases affect millions worldwide, with many patients facing limited treatment options for severe and rare conditions.
argenx has partnered with Monash to advance a novel antibody molecule currently in pre-clinical development. Initiated through argenx’s Immunology Innovation Program, the collaboration spans early research through to potential clinical trials, combining Monash’s research expertise with argenx’s global drug development capabilities to target diseases with significant unmet need.